- Home
- REE vs MBRX Comparison
REE vs MBRX Comparison
Compare REE & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- MBRX
- Stock Information
- Founded
- REE 2011
- MBRX 2015
- Country
- REE Israel
- MBRX United States
- Employees
- REE N/A
- MBRX N/A
- Industry
- REE Auto Manufacturing
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- MBRX Health Care
- Exchange
- REE Nasdaq
- MBRX Nasdaq
- Market Cap
- REE 18.5M
- MBRX 17.1M
- IPO Year
- REE N/A
- MBRX 2016
- Fundamental
- Price
- REE $0.72
- MBRX $0.37
- Analyst Decision
- REE Strong Buy
- MBRX Strong Buy
- Analyst Count
- REE 2
- MBRX 4
- Target Price
- REE $11.75
- MBRX $5.00
- AVG Volume (30 Days)
- REE 66.5K
- MBRX 4.8M
- Earning Date
- REE 09-16-2025
- MBRX 11-07-2025
- Dividend Yield
- REE N/A
- MBRX N/A
- EPS Growth
- REE N/A
- MBRX N/A
- EPS
- REE N/A
- MBRX N/A
- Revenue
- REE $183,000.00
- MBRX N/A
- Revenue This Year
- REE $6,661.20
- MBRX N/A
- Revenue Next Year
- REE $2,240.01
- MBRX N/A
- P/E Ratio
- REE N/A
- MBRX N/A
- Revenue Growth
- REE N/A
- MBRX N/A
- 52 Week Low
- REE $0.53
- MBRX $0.25
- 52 Week High
- REE $11.72
- MBRX $3.65
- Technical
- Relative Strength Index (RSI)
- REE 53.85
- MBRX 35.17
- Support Level
- REE $0.65
- MBRX $0.36
- Resistance Level
- REE $0.75
- MBRX $0.42
- Average True Range (ATR)
- REE 0.04
- MBRX 0.04
- MACD
- REE 0.01
- MBRX -0.00
- Stochastic Oscillator
- REE 61.33
- MBRX 9.05
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.